Why the study?
Does early initiation of apixaban tailored to infarct size improve functional outcomes in patients with acute ischemic stroke?
Does early initiation of apixaban tailored to infarct size improve functional outcomes in patients with acute ischemic stroke?
Early initiation of apixaban tailored to infarct size may improve functional outcomes and reduce stroke progression in acute ischemic stroke without increasing bleeding risk.
Supports early infarct-size-tailored apixaban in acute ischemic stroke; extends RCT evidence on post-stroke anticoagulation timing.
Our findings suggest that early initiation of apixaban, tailored to infarct size, could serve as a viable strategy to enhance functional outcomes. This approach may potentially decrease stroke progression and early recurrence without elevating the risk of sHT.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: